News | May 13, 2023
Cipla reports Q4 FY 23 consolidated PAT at Rs. 525.65 Cr
Cipla has reported total income of Rs. 5873.93 crores during the period ended March 31, 2023
Cipla has reported total income of Rs. 5873.93 crores during the period ended March 31, 2023
This decision will accelerate growth for both its pharma & consumer healthcare businesses in India
Acquisition of XinThera provides Gilead with precision small molecules focused on PARP1 and MK2 Inhibitors
The company has reported total income of Rs. 187.75 crores during the period ended March 31, 2023
Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time
Pandemic was the opportunity for Ayush to develop their science and Ayush did it by developing Ayush 64, etc
The company has reported total income of Rs. 211.62 crores during the period ended March 31, 2023
Lucid-MS is a new drug candidate for the treatment of multiple sclerosis
The company has reported total income of Rs. 4467.35 crores during the quarter ended March 31, 2023
‘Fibrotic disease’ is a term that covers a range of diseases characterized by uncontrolled and progressive fibrosis,
Subscribe To Our Newsletter & Stay Updated
